Cannara Biotech Inc (LOVFF) fair value: what the stock is really worth
As of Sep 30, 2026: fair value of Cannara Biotech Inc $2.45, price $1.48, upside +65.5%, quality 66 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Cannara Biotech Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $0.3971 – $1.53 · fair‑value band $1.39 – $4.11 · the $1.48 price screens below the $2.45 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Cannara Biotech in your weekly email
Every Wednesday you see whether Cannara Biotech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivative products in Canada. The company operates in two segment Cannabis operations and Real estate operations. It offers its products under TRIBAL, nugz, and ORCHID CBD brand name.
Show more
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivative products in Canada. The company operates in two segment Cannabis operations and Real estate operations. It offers its products under TRIBAL, nugz, and ORCHID CBD brand name. The company sells its products through wholesalers and online merchandisers. In addition, it engages in the real estate operations. Cannara Biotech Inc. was incorporated in 2017 and is headquartered in Saint-Laurent, Canada.
Stock analysis
Cannara Biotech Inc (LOVFF) currently trades at $1.48, while our model-based Fair Value estimate is $2.45, implying the stock looks roughly 39.6% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $4.32 per share, and 20 of the 24 models we run sit above the $1.48 price.
Bear case: the Asset-Based group reads lowest at $0.4900, and 4 of the 24 models stay below the price. Evidence for this calculation is medium.
Scenario range: $1.39 (bear) to $4.11 (bull), the price of $1.48 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 66/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Cannara Biotech Inc reported revenue of C$107M in FY2025 versus C$16.3M in FY2021, a compound +60.2%/yr. Reported net income was C$13.1M in FY2025.
Key figures
Market cap $135M · P/E ratio 18.5 · P/S ratio 2.26 · EPS (TTM) $0.0800 · Net margin 12.2% · Return on equity 9.5% · Return on assets (EBIT) 6.2% · Operating margin 12.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 3% below its 52-week high and 32% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 66%, LOVFF screens cheaper than that median.
Fair Value models
Bear $1.39Fair Value $2.45Bull $4.11
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then ($0.0800 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.90/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+31.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+44.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+112.5%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+119.8%
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
≈ +53.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+53.2%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−482% → 20%
⚠ Approximate: the rate leans on 2025, which sits 100% above its own trend.
Growth Forecast
Price in line with expectations
The price assumes less growth than the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+9.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+12.1%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in CAD, Canada: IMF forecast 2.1% a year to 2030, 2.6% from 2016 to 2025) that is about +6.8% a year for the price and +9.7% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 569 stocks
Beats the industry median on 11/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score66 · Top 25%
Fair Value upside+73.5% · Top 25%
Profitability
Return on equity (TTM)9.5% · Above median
Return on assets6.5% · Top 25%
Net margin (TTM)9.0% · Above median
Operating margin (TTM)12.4% · Above median
Growth and dividend
Revenue growth2.6% · Below median
Balance sheet
Debt / equity0.28× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Cannara Biotech Inc (LOVFF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $2.45 versus a price of $1.48, about +66% upside (undervalued).
What is the fair value of LOVFF?
Our model-based fair value for Cannara Biotech Inc is $2.45 (as of Sep 24, 2026), built from audited fundamentals. The current price: $1.48.
What is the quality score of LOVFF?
Cannara Biotech Inc has a Quality Score of 66/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cannara Biotech Inc (LOVFF)?
Our model-based price target is the fair value of $2.45 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario $1.39, optimistic scenario $4.11. It is a calculation from audited fundamentals, not an analyst target.
What is the Cannara Biotech Inc stock forecast for 2026?
Our models put fair value at $2.45, about +66% upside versus a price of $1.48 (undervalued). Cautious scenario $1.39, optimistic scenario $4.11. The calculation is refreshed regularly with new filings.
What is the revenue of Cannara Biotech Inc (LOVFF)?
Cannara Biotech Inc reported trailing-twelve-month revenue of about C$113M (latest available figure, as of Sep 24, 2026).
What growth is priced into Cannara Biotech Inc (LOVFF)?
For today's price to be fair in a discounted-cash-flow model, Cannara Biotech Inc would have to grow free cash flow by +9.1 % per year for five years (discount rate 11.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +112.5 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of LOVFF use?
Our models discount Cannara Biotech Inc at 11.2 %: a base by market capitalisation (micro), damped by beta 0.40, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Cannara Biotech Inc that is +9.1 % per year a year over ten years, using the same discount rate (11.2 %) and the same formula as our fair value.
How much growth has Cannara Biotech Inc (LOVFF) delivered so far?
Over the past 5 years revenue at Cannara Biotech Inc grew +112.5 % a year. The price currently implies +9.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Cannara Biotech Inc (LOVFF) growing?
The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into Cannara Biotech Inc (+9.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Cannara Biotech Inc (LOVFF)?
The free-cash-flow yield on the price is 7.08 %: that much free cash flow Cannara Biotech Inc produces per unit of market value. When it exceeds the discount rate of our models (11.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Cannara Biotech Inc (LOVFF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cannara Biotech Inc it is $2.45 per share (as of Sep 24, 2026), against a price of $1.48. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Cannara Biotech Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, LOVFF trades below its calculated fair value: price $1.48, fair value $2.45, a gap of about +66% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LOVFF?
No. The price is what the market pays today ($1.48); the fair value is what the company's own numbers justify ($2.45). For Cannara Biotech Inc the two are $0.9700 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cannara Biotech Inc worth?
The market values Cannara Biotech Inc at about $135M (market capitalisation, as of Sep 24, 2026). Per share that is $1.48; our models calculate a fair value of $2.45 per share.
What do the bullish and bearish scenarios say about LOVFF?
Our models span a range for Cannara Biotech Inc: cautious scenario $1.39, base $2.45, optimistic $4.11 per share (as of Sep 24, 2026, price $1.48). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of LOVFF?
Cannara Biotech Inc trades at a price-to-earnings ratio of 18.5 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $2.45 is built from several models across several years. Other multiples: P/B 1.3, P/S 1.2, EV/EBITDA 6.2.
How solid is the balance sheet of Cannara Biotech Inc (LOVFF)?
Balance-sheet figures for Cannara Biotech Inc (as of Sep 24, 2026): return on equity 9.5%, debt of 0.28 per unit of equity. They feed the Quality Score of 66/100, which measures business quality independently of the share price.
How far is LOVFF from its 52-week high?
Cannara Biotech Inc trades at $1.48, about 3% below its 52-week high of $1.53 and 32% above the low of $1.12 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of $2.45 is for.
Which stocks are comparable to Cannara Biotech Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cannara Biotech Inc stock attractive at the current price?
The data as of Sep 24, 2026: price $1.48, calculated fair value $2.45 (+66%), Quality Score 66/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LOVFF calculated?
We run Cannara Biotech Inc through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $2.45, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Cannara Biotech Inc currently trades 40 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cannara Biotech Inc (LOVFF)?
The closing price on Sep 30, 2026 was $1.48. Our model-based fair value is $2.45, about +66% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cannara Biotech Inc right now?
The model range is unusually wide ($1.39 to $4.11). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid quality (66/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Cannara Biotech Inc
How large is the market capitalisation of Cannara Biotech Inc (LOVFF)?
The market capitalisation of Cannara Biotech Inc is $135M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cannara Biotech Inc (LOVFF)?
The price-to-sales ratio of Cannara Biotech Inc is 2.26 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Cannara Biotech Inc (LOVFF)?
Earnings per share at Cannara Biotech Inc are $0.0800 (price ÷ EPS = P/E 18.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Cannara Biotech Inc (LOVFF)?
The net margin of Cannara Biotech Inc is 12.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Cannara Biotech Inc (LOVFF)?
The return on equity (ROE) of Cannara Biotech Inc is 9.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cannara Biotech Inc (LOVFF)?
On an EBIT basis the return on assets of Cannara Biotech Inc is 6.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cannara Biotech Inc (LOVFF)?
The operating margin of Cannara Biotech Inc is 12.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cannara Biotech Inc (LOVFF)?
Revenue at Cannara Biotech Inc is growing +2.6% versus a year earlier (3y avg +44.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Cannara Biotech Inc (LOVFF)?
Earnings per share at Cannara Biotech Inc are growing −52.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Cannara Biotech Inc (LOVFF) carry?
The net debt of Cannara Biotech Inc is C$26.8M (fiscal year 2025, ≈ 2.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Cannara Biotech Inc in the live analysis
One click puts Cannara Biotech Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Some data
Sep 24, 2026